Free Trial

Akebia Therapeutics (AKBA) Competitors

Akebia Therapeutics logo
$3.56 -0.28 (-7.29%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$3.56 +0.00 (+0.03%)
As of 07/25/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AKBA vs. SRRK, ZLAB, ACLX, PTCT, ACAD, VKTX, SWTX, AAPG, MLTX, and PTGX

Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Scholar Rock (SRRK), Zai Lab (ZLAB), Arcellx (ACLX), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), Ascentage Pharma Group International (AAPG), MoonLake Immunotherapeutics (MLTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

Akebia Therapeutics vs. Its Competitors

Akebia Therapeutics (NASDAQ:AKBA) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Scholar Rock has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -24.51%. Akebia Therapeutics' return on equity of 0.00% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Akebia Therapeutics-24.51% N/A -18.92%
Scholar Rock N/A -118.22%-82.01%

In the previous week, Scholar Rock had 3 more articles in the media than Akebia Therapeutics. MarketBeat recorded 9 mentions for Scholar Rock and 6 mentions for Akebia Therapeutics. Scholar Rock's average media sentiment score of 1.33 beat Akebia Therapeutics' score of 0.95 indicating that Scholar Rock is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akebia Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Scholar Rock
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Akebia Therapeutics currently has a consensus target price of $6.75, suggesting a potential upside of 89.61%. Scholar Rock has a consensus target price of $42.67, suggesting a potential upside of 9.54%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akebia Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Scholar Rock
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13

Akebia Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.

Akebia Therapeutics has higher revenue and earnings than Scholar Rock. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akebia Therapeutics$160.18M5.84-$69.41M-$0.21-16.95
Scholar Rock$33.19M111.43-$246.29M-$2.53-15.40

33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 3.0% of Akebia Therapeutics shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Akebia Therapeutics and Scholar Rock tied by winning 8 of the 16 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKBA vs. The Competition

MetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$934.98M$2.51B$5.74B$9.54B
Dividend YieldN/A1.77%4.71%4.02%
P/E Ratio-16.959.5828.4120.06
Price / Sales5.84668.34443.6492.77
Price / CashN/A164.0436.1858.54
Price / Book-15.485.168.655.87
Net Income-$69.41M$30.99M$3.25B$258.89M
7 Day Performance-7.77%7.73%4.31%3.75%
1 Month Performance-2.47%19.78%11.60%12.29%
1 Year Performance147.22%-1.37%35.38%17.86%

Akebia Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKBA
Akebia Therapeutics
3.801 of 5 stars
$3.56
-7.3%
$6.75
+89.6%
+147.2%$934.98M$160.18M-16.95430High Trading Volume
SRRK
Scholar Rock
3.4298 of 5 stars
$41.12
+1.0%
$42.67
+3.8%
+319.7%$3.90B$33.19M-16.25140
ZLAB
Zai Lab
3.127 of 5 stars
$34.66
+3.2%
$54.28
+56.6%
+97.1%$3.85B$418.33M-13.921,869Positive News
Gap Down
ACLX
Arcellx
2.2744 of 5 stars
$69.39
+2.7%
$111.23
+60.3%
+10.7%$3.82B$107.94M-23.2180News Coverage
Positive News
PTCT
PTC Therapeutics
4.5285 of 5 stars
$47.86
+0.5%
$65.00
+35.8%
+31.2%$3.79B$806.78M7.351,410News Coverage
Positive News
Analyst Revision
ACAD
ACADIA Pharmaceuticals
4.1552 of 5 stars
$22.28
-1.2%
$27.88
+25.1%
+21.5%$3.73B$957.80M16.26510Positive News
Analyst Forecast
VKTX
Viking Therapeutics
4.8466 of 5 stars
$31.94
-0.2%
$87.15
+172.9%
-47.8%$3.59BN/A-27.7720Trending News
Earnings Report
Analyst Forecast
Analyst Revision
SWTX
SpringWorks Therapeutics
1.2683 of 5 stars
$46.99
flat
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230
AAPG
Ascentage Pharma Group International
N/A$39.71
-1.7%
N/AN/A$3.46B$134.35M0.00600Lockup Expiration
Gap Down
MLTX
MoonLake Immunotherapeutics
2.2812 of 5 stars
$53.57
+0.9%
$74.50
+39.1%
+23.0%$3.43BN/A-23.292News Coverage
Positive News
Options Volume
PTGX
Protagonist Therapeutics
1.3724 of 5 stars
$55.22
-0.5%
$66.10
+19.7%
+36.9%$3.42B$434.43M73.63120News Coverage
Insider Trade

Related Companies and Tools


This page (NASDAQ:AKBA) was last updated on 7/27/2025 by MarketBeat.com Staff
From Our Partners